KRON Kronos Bio Inc.

25.73
+0.93  (+4%)
Previous Close 24.8
Open 24.68
52 Week Low 19.6
52 Week High 39.605
Market Cap $1,442,677,343
Shares 56,069,854
Float 39,356,586
Enterprise Value $1,021,824,379
Volume 174,069
Av. Daily Volume 240,160
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
KB-0742
Solid tumors
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Entospletinib
Acute myeloid leukemia (AML)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Entospletinib
Acute myeloid leukemia (AML)
Phase 1/2
Phase 1/2
Phase 1/2 FLT3 mt AML trial to be initiated 2021.

Latest News

  1. Virtual R&D Day on May 25 to unveil SYK portfolio development strategy and highlight momentum of CDK9 inhibitor program and differentiated drug discovery platform

    Preclinical data for KB-0742 presented at the American Association for Cancer Research (AACR) Annual Meeting demonstrated sustained inhibition of tumor growth in multiple cancers

    $440.6 million in cash, cash equivalents and investments as of March 31, 2021

    SAN MATEO, Calif. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and first quarter financial results.

    "With continued progress in our preclinical and clinical programs and…

    Virtual R&D Day on May 25 to unveil SYK portfolio development strategy and highlight momentum of CDK9 inhibitor program and differentiated drug discovery platform

    Preclinical data for KB-0742 presented at the American Association for Cancer Research (AACR) Annual Meeting demonstrated sustained inhibition of tumor growth in multiple cancers

    $440.6 million in cash, cash equivalents and investments as of March 31, 2021

    SAN MATEO, Calif. and CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today reported recent business progress and first quarter financial results.

    "With continued progress in our preclinical and clinical programs and significant milestones expected this year, we look forward to hosting a research and development day to present our pipeline and unveil our development strategy for both of our clinical-stage SYK inhibitors entospletinib and lanraplenib," said Norbert Bischofberger, Ph.D., president and CEO. "We recently showcased progress with our CDK9 program at the AACR annual meeting in April, where we presented preclinical data indicating that KB-0742 could have utility in the treatment of MYC-amplified cancers. We look forward to sharing more about our development plans for this compound at our research and development day."

    Dr. Bischofberger added: "I would also like to take this opportunity to reflect on the recent passing of our Board Member, Dr. John C. Martin, a dear friend and mentor, and to convey our deepest sympathies to John's family and everyone who was fortunate enough to have known him."

    Recent Highlights

    • Presented preclinical data for KB-0742, the company's potent oral, highly selective cyclin dependent kinase 9 (CDK9) inhibitor, at the American Association for Cancer Research (AACR) Annual Meeting. The data showed that CDK9 inhibition on an intermittent dosing schedule with KB-0742 resulted in sustained inhibition of tumor growth in multiple types of solid tumors, and suggested that genomic amplification of MYC, a well-characterized transcription factor and a long-recognized driver of cancer, is a key feature in defining sensitivity to CDK9 inhibition.



    • Announced the appointment of Taiyin Yang, Ph.D., to its board of directors. Dr. Yang currently serves as the executive vice president of Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc., and has more than four decades of experience developing and manufacturing medicines in a variety of therapeutic categories.



    • Announced a positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for spleen tyrosine kinase (SYK) inhibitor entospletinib. Kronos Bio will proceed with its plan to assess measurable residual disease (MRD) negative complete response (CR) as the primary endpoint in a registrational Phase 3 trial to support potential accelerated approval of entospletinib in patients newly diagnosed with NPM1-mutated acute myeloid leukemia (AML). The company plans to initiate the Phase 3 trial in mid-2021, with MRD negative CR data expected in the second half of 2023.



    • Announced the first patient was dosed in the Phase 1/2 clinical trial of KB-0742, which is being developed to treat MYC-amplified solid tumors.

    Pipeline updates planned at upcoming Virtual R&D Day on May 25, 2021

    • Unveil the development strategy for the company's SYK inhibitors entospletinib and lanraplenib in AML. Kronos Bio executives will be joined by Eytan M. Stein, M.D., assistant attending physician and director, Program for Drug Development in Leukemia, Leukemia Service, Department of Medicine at Memorial Sloan Kettering Cancer Center, who will provide an overview of AML and the current treatment landscape.



    • Highlight the opportunity to target MYC through CDK9 inhibition with KB-0742, including a review of preclinical data, expectations for initial safety, pharmacokinetic and pharmacodynamic data anticipated in the fourth quarter of 2021 and potential populations for the expansion cohorts in the second stage of the company's Phase 1/2 clinical trial.



    • Provide an overview of the company's differentiated drug discovery platform and potential future pipeline programs.

    The live webinar will begin at 1 p.m. ET on Tuesday, May 25, 2021, and will conclude at approximately 4:00 p.m. ET. Registration is accessible on the Investors & Media section of the company's website at www.kronosbio.com. A replay of the webcast will be archived and available following the event.

    First Quarter Financial Highlights

    Cash, Cash Equivalents and Investments: As of March 31, 2021, cash, cash equivalents and investments totaled $440.6 million.

    R&D Expenses: Research and development expenses were $17.6 million for the first quarter of 2021, which includes $2.5 million in non-cash stock-based compensation expense. R&D expenses for the quarter were primarily driven by costs associated with initiating and conducting the company's clinical trials.

    G&A Expenses: General and administrative expenses were $8.6 million for the first quarter of 2021, which includes $2.7 million in non-cash stock-based compensation expense.

    Net Loss: Net loss for the first quarter of 2021 was $26.1 million, or $0.48 per share, including non-cash stock-based compensation expense of $5.2 million.

    About Kronos Bio, Inc.

    Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio's lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

    Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.

    Forward-Looking Statements

    Statements in this press release that are not statements of historical fact are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release, in some cases, uses terms such as "progress," "expected," "look forward," "unveil," "proceed," "assess," "plans," "initiate," "developed," "provide," "planned," "expectations" "anticipated," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding Kronos Bio's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Kronos Bio's plans to conduct a Phase 1/2 clinical trial of KB-0742 in patients with advanced solid tumors and the expected timing thereof; the design of such planned Phase 1/2 clinical trial, including to establish clinical proof of concept to enable potential further development; Kronos Bio's plans to conduct a Phase 3 trial of entospletinib in NPM1-mutated AML, and the timing thereof; and other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: whether Kronos Bio will be able to complete the Phase 1/2 clinical trial of KB-0742 and the planned clinical trial of entospletinib on the timeline expected, if at all, including due to risks associated with the COVID-19 pandemic and risks inherent in the clinical development of novel therapeutics; risks related to Kronos Bio's lack of experience as a company in conducting clinical trials; the risk that results of preclinical studies and early clinical trials are not necessarily predictive of future results; the risk that due to the relatively small number of patients that Kronos Bio plans to dose in the planned Phase 1/2 KB-0742 clinical trial, the results from the planned Phase 1/2 clinical trial, once completed, may be less reliable than results achieved in larger clinical trials, which may hinder Kronos Bio's efforts to further develop and obtain regulatory approval for KB-0742; and risks associated with the sufficiency of Kronos Bio's cash resources and need for additional capital. These and other risks are described in greater detail in Kronos Bio's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on March 23, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release and are based on management's assumptions and estimates as of such date. Except as required by law, Kronos Bio assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

    Kronos Bio, Inc.

    Statements of Operations and Comprehensive Loss

    (in thousands, except share and per share amounts)

    (Unaudited)

      Three months ended March 31,
       2021   2020 
    Operating expenses:    
    Research and development $17,594  $6,195 
    General and administrative  8,584   1,154 
    Total operating expenses  26,178   7,349 
    Loss from operations  (26,178)  (7,349)
    Other income (expense), net:    
    Interest expense     (1)
    Interest and other income, net  92   355 
    Total other income (expense), net  92   354 
    Net loss  (26,086)  (6,995)
    Other comprehensive income (loss):    
    Net unrealized gain (loss) on available-for-sale securities  (4)  158 
    Net comprehensive loss $(26,090) $(6,837)
    Net loss per share, basic and diluted $(0.48) $(1.23)
    Weighted-average shares of common stock, basic and diluted  54,152,656   5,694,832 
             

    Kronos Bio, Inc.

    Selected Balance Sheet Data

    (in thousands, except share and per share amounts)

    (Unaudited)

      March 31, 2021 December 31, 2020
    Cash, cash equivalents and investments $440,608  $462,062 
    Total assets 487,961  511,964 
    Total liabilities 42,704  46,445 
    Total stockholders' equity (deficit) 445,257  465,519 
           

    Company contact:

    Stephanie Yao

    Executive Director, Investor Relations and Corporate Communications

    650-525-6605

    Investors:

    Claudia Styslinger

    Argot Partners

    212-600-1902

    Media:

    Sheryl Seapy

    Real Chemistry

    949-903-4750



    Primary Logo

    View Full Article Hide Full Article
  2. SAN MATEO, Calif. and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the Bank of America Securities 2021 Health Care Conference on Thursday, May 13, 2021 at 1:15 p.m. ET.

    The fireside chat will be webcast live from the Investors & Media section of the company's website at www.kronosbio.com. A replay of the webcast will be archived and available for one month following the event.

    About Kronos Bio, Inc.
    Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of…

    SAN MATEO, Calif. and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the Bank of America Securities 2021 Health Care Conference on Thursday, May 13, 2021 at 1:15 p.m. ET.

    The fireside chat will be webcast live from the Investors & Media section of the company's website at www.kronosbio.com. A replay of the webcast will be archived and available for one month following the event.

    About Kronos Bio, Inc.

    Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio's lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

    Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.

    Company contact:

    Stephanie Yao

    Executive Director, Investor Relations and Corporate Communications

    650-525-6605

    Investors:

    Claudia Styslinger

    Argot Partners

    212-600-1902

    Media:

    Sheryl Seapy

    Real Chemistry

    949-903-4750



    Primary Logo

    View Full Article Hide Full Article
  3. MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition

    Pan-cancer anti-tumor activity, including in tumors exposed to prior lines of therapy, seen with intermittent dosing of KB-0742

    Initial safety, pharmacokinetic and pharmacodynamic data from the ongoing Phase 1/2 clinical trial for KB-0742 expected in fourth quarter of 2021

    SAN MATEO, Calif. and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today presented preclinical data for KB-0742, a highly selective, orally bioavailable cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-amplified solid tumors. The data showed that CDK9…

    MYC genomic amplification found to be a key driver of sensitivity to CDK9 inhibition

    Pan-cancer anti-tumor activity, including in tumors exposed to prior lines of therapy, seen with intermittent dosing of KB-0742

    Initial safety, pharmacokinetic and pharmacodynamic data from the ongoing Phase 1/2 clinical trial for KB-0742 expected in fourth quarter of 2021

    SAN MATEO, Calif. and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today presented preclinical data for KB-0742, a highly selective, orally bioavailable cyclin dependent kinase 9 (CDK9) inhibitor being developed to treat MYC-amplified solid tumors. The data showed that CDK9 inhibition on an intermittent dosing schedule with KB-0742 resulted in sustained inhibition of tumor growth in multiple types of solid tumors. The data also suggested that genomic amplification of MYC, a well-characterized transcription factor and a long-recognized driver of cancer, is a key factor of sensitivity to CDK9 inhibition. These findings were presented in a poster session today at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

    "These preclinical data support our approach to leveraging CDK9 inhibition to treat cancers that express high levels of MYC. Furthermore, the anti-tumor activity seen with intermittent dosing of KB-0742 in multiple cancer cell lines suggests that constant inhibition may not be needed in order to achieve desired target coverage," said Jorge DiMartino, M.D., Ph.D., chief medical officer and executive vice president, clinical development. "Having recently initiated our clinical development program for KB-0742, we are eager to determine if these preclinical results translate to the clinic. If this proves to be the case, we believe KB-0742 has the potential to be an important advance in the treatment of MYC-amplified solid tumors."

    Kronos Bio researchers, in collaboration with colleagues from Baylor College of Medicine, the University of Washington and the Broad Institute, conducted several experiments to better define molecular sensitivity to transcriptional inhibition by profiling the sensitivity of various tumor types to KB-0742. They found that MYC genomic amplification emerged as a key driver of CDK9 inhibitor sensitivity, especially in non-small cell lung cancer. Additionally, MYC amplification and over-expression in tumor cells and patient-derived xenografts conferred sensitivity to CDK9 inhibition. In these CDK9-sensitive models, suppression of oncogenic transcription for more than eight hours was followed by cell death (apoptosis). Importantly, CDK9 inhibitor sensitivity was observed for both treatment-naïve and heavily pretreated patient samples, and CDK9 inhibition on an intermittent dosing schedule achieved sustained target coverage, as evidenced by both direct readouts of CDK9 activity and corresponding transcriptional response, ultimately inhibiting tumor growth in multiple solid tumor types.

    The poster is now available on the AACR Annual Meeting website and in the Publications section of the Kronos Bio website. Details of the presentation are as follows:

    • Title: CDK9 inhibition is selective for transcriptionally addicted tumors harboring MYC genomic amplifications
    • Abstract Number: 1141
    • Session Category: Experimental and Molecular Therapeutics
    • Session Title: Epigenetic Targets

    In February, Kronos Bio initiated a Phase 1/2 clinical trial for KB-0742 in patients with advanced solid tumors or non-Hodgkin lymphoma. The company expects to report initial safety, pharmacokinetic and pharmacodynamic data from the dose-escalation stage of the study in the fourth quarter of this year. Initial data from the study's expansion cohorts are expected in 2022.

    About KB-0742

    KB-0742 is a highly selective, orally bioavailable inhibitor of cyclin dependent kinase 9 (CDK9) in development for the treatment of MYC-amplified solid tumors. CDK9 is a global regulator of transcription and plays an essential role in both the expression and function of MYC, a well-characterized transcription factor and a long-recognized driver of cancer that is amplified in approximately 30% of solid tumors, including those affecting the lungs, ovaries, esophagus, breast, stomach, pancreas and liver.1 KB-0742 was generated and optimized from a compound that was identified using the company's proprietary small molecule microarray (SMM) screening platform.

    About the Small Molecule Microarray (SMM) Screening Platform

    Kronos Bio leverages its SMM screening platform to conduct high-throughput screens against traditionally undruggable target proteins, in particular transcription factors. The SMM platform directly addresses the historical challenges of targeting transcription factors by screening in conditions that preserve their associated context-dependent structures and multi-protein complexes. Using the company's library of approximately 240,000 compounds in microarray format on slides, Kronos Bio screens for small molecule binders of the target transcription factor in context-relevant tumor nuclear lysates. Hits derived from SMM screening have the potential to act through a variety of mechanisms against various members of a transcription factor's complex and, as such, hits are characterized for their ability to selectively modulate an oncogenic transcription factor's activity as important criteria for further lead selection and optimization.

    About Kronos Bio, Inc.

    Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio's lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

    Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.

    Forward-Looking Statements

    Statements in this press release that are not statements of historical fact are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release, in some cases, uses terms such as "expected," "leveraging," "suggest," "achieve," "determine," "translate," "believe," "potential" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding Kronos Bio's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the potential of KB-0742 to be an important advance in the treatment of MYC-amplified solid tumors; the design of the KB-0742 Phase 1/2 clinical trial, including to establish clinical proof of concept to enable potential further development; the timing of any results, including PK/PD data, from the KB-0742 Phase 1/2 clinical trial; and other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: whether Kronos Bio will be able to complete the Phase 1/2 clinical trial of KB-0742, including due to risks associated with the COVID-19 pandemic and risks inherent in the clinical development of novel therapeutics; risks related to Kronos Bio's lack of experience as a company in conducting clinical trials; the risk that results of preclinical studies and early clinical trials are not necessarily predictive of future results; the risk that due to the relatively small number of patients that Kronos Bio plans to dose in the planned Phase 1/2 KB-0742 clinical trial, the results from such trial, once completed, may be less reliable than results achieved in larger clinical trials, which may hinder Kronos Bio's efforts to further develop and obtain regulatory approval for KB-0742; and risks associated with the sufficiency of Kronos Bio's cash resources and need for additional capital. These and other risks are described in greater detail in Kronos Bio's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 23, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release and are based on management's assumptions and estimates as of such date. Except as required by law, Kronos Bio assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

    References

    1. Schaub FX, Dhankani V, Berger AC, et al. Pan-cancer alterations of the MYC oncogene and Its proximal network across the cancer genome atlas. Cell Syst. 2018:6(3):282-300.

    Company contact:

    Stephanie Yao

    Executive Director, Investor Relations and Corporate Communications

    650-525-6605

    Investors:

    Claudia Styslinger

    Argot Partners

    212-600-1902

    Media:

    Sheryl Seapy

    Real Chemistry

    949-903-4750



    Primary Logo

    View Full Article Hide Full Article
  4. SAN MATEO, Calif. and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON) today commented on the passing of John C. Martin, Ph.D., board member and early investor in the company.

    "On behalf of the employees and Board of Directors at Kronos Bio, I am deeply saddened by John's passing. An exceptional scientist and business leader, John has made immeasurable contributions to the life sciences community, our company and numerous other organizations. Most importantly, he has helped millions of people around the world through the medicines we developed throughout our nearly three decades as colleagues. He leaves a lasting legacy that will benefit patients around the world for years to come," Norbert Bischofberger…

    SAN MATEO, Calif. and CAMBRIDGE, Mass., March 31, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON) today commented on the passing of John C. Martin, Ph.D., board member and early investor in the company.

    "On behalf of the employees and Board of Directors at Kronos Bio, I am deeply saddened by John's passing. An exceptional scientist and business leader, John has made immeasurable contributions to the life sciences community, our company and numerous other organizations. Most importantly, he has helped millions of people around the world through the medicines we developed throughout our nearly three decades as colleagues. He leaves a lasting legacy that will benefit patients around the world for years to come," Norbert Bischofberger, Ph.D., president and CEO of Kronos Bio. "John was one of my dearest friends and a great mentor, and I will miss him terribly. We extend our deepest sympathies to John's family and everyone who was fortunate to have known him."

    Dr. Martin joined Gilead Sciences in 1990 as vice president for research and development. He served as president and chief executive officer from 1996 through May 2008, as chair and chief executive officer from June 2008 through March 2016 and was executive chair from March 2016 through March 2019. During his tenure at Gilead, Dr. Martin oversaw the development of the first single-tablet regimen for HIV, marking the beginning of an era of innovation that transformed the treatment paradigm for HIV/AIDS and turned this deadly disease into a chronic, manageable condition. Under Dr. Martin's guidance, Gilead grew to become a leader in HIV and other infectious diseases.

    Dr. Martin was especially passionate about ensuring people around the world, particularly patients in Africa and resource-limited regions, have access to healthcare and important medicines. In 2014, he established The John C. Martin Foundation to help advance the control and prevention of endemic illnesses in underserved populations around the world. Through this Foundation, Dr. Martin supported projects focused on improving the tracking, care and treatment of patients with HIV and hepatitis and organizations working to end viral hepatitis worldwide.

    Prior to joining Gilead, he held several leadership positions at Bristol-Myers Squibb and Syntex Corporation. Dr. Martin has been a Kronos Bio board member since 2018 and was one of the earliest investors of the company.

    About Kronos Bio, Inc.

    Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio's lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

    Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.

    Company contact:

    Stephanie Yao

    Executive Director, Investor Relations and Corporate Communications

    650-525-6605

    Investors:

    Claudia Styslinger

    Argot Partners

    212-600-1902

    Media:

    Sheryl Seapy

    Real Chemistry

    949-903-4750



    Primary Logo

    View Full Article Hide Full Article
  5. SAN MATEO, Calif. and CAMBRIDGE, Mass., March 26, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Taiyin Yang, Ph.D., to the company's board of directors. Dr. Yang has more than four decades of experience in developing and manufacturing medicines in a variety of therapeutic categories. Additionally, Jakob Loven has notified the company that he will not stand for re-election at the company's 2021 Annual Meeting of Stockholders.

    "On behalf of the board of directors and senior management at Kronos Bio, I am pleased to welcome Taiyin to the board at this exciting time in our growth as a company. Taiyin is a highly respected and…

    SAN MATEO, Calif. and CAMBRIDGE, Mass., March 26, 2021 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Taiyin Yang, Ph.D., to the company's board of directors. Dr. Yang has more than four decades of experience in developing and manufacturing medicines in a variety of therapeutic categories. Additionally, Jakob Loven has notified the company that he will not stand for re-election at the company's 2021 Annual Meeting of Stockholders.

    "On behalf of the board of directors and senior management at Kronos Bio, I am pleased to welcome Taiyin to the board at this exciting time in our growth as a company. Taiyin is a highly respected and experienced business leader with a proven track record across product development, commercial manufacturing and quality operations. Her counsel and expertise will be invaluable as we continue to advance our pipeline programs into later clinical development and approach commercialization," said Norbert Bischofberger, Ph.D., president and CEO of Kronos Bio. "I would also like to thank Jakob for his dedicated service to the company and his many contributions over the years to help us reach where we are today."

    Dr. Yang currently serves as the executive vice president of Pharmaceutical Development and Manufacturing at Gilead Sciences Inc., with responsibility for all the company's investigational compounds and marketed products. Under her leadership, Gilead developed the world's first HIV single tablet regimen and advanced more than 25 compounds from early-stage development to commercialization, reaching millions of people around the world. Dr. Yang joined Gilead in 1993, became the senior vice president of Pharmaceutical Development and Manufacturing in 2005, and was appointed to her current role in 2015. Prior to joining Gilead, Dr. Yang worked at Syntex Corporation for more than a decade, where she contributed to the development and commercialization of more than 10 medicines.

    "I am excited to join Kronos Bio's board of directors," said Dr. Yang. "I look forward to contributing to the company's future growth alongside my fellow board members and company senior management to help advance truly innovative drug candidates that have the potential to transform the lives of people affected by cancer."

    In addition to Kronos Bio, Dr. Yang is currently a member of the board of directors of Kodiak Sciences. She serves as an executive sponsor of the Gilead Asian Interest Network and is a member of the Expert Scientific Advisory Committee of Medicines for Malaria Venture. This year, Dr. Yang became a fellow of the American Institute for Medical and Biological Engineering. Dr. Yang holds a B.S. in chemistry from National Taiwan University and a Ph.D. in organic chemistry from the University of Southern California.

    About Kronos Bio, Inc.

    Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio's lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

    Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.

    Forward-Looking Statements

    Statements in this press release that are not statements of historical fact are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release, in some cases, uses terms such as "believe," "potential," "continue," "advance," "approach," "look forward," "future growth," "advance" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding Kronos Bio's ability to advance its pipeline programs into later clinical development and commercialization, and other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: due to risks associated with the COVID-19 pandemic and risks inherent in the clinical development of novel therapeutics; risks related to Kronos Bio's lack of experience as a company in conducting clinical trials; the risk that results of preclinical studies and early clinical trials are not necessarily predictive of future results; and risks associated with the sufficiency of Kronos Bio's cash resources and need for additional capital. These and other risks are described in greater detail in Kronos Bio's filings with the Securities and Exchange Commission (SEC), including under the heading "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 23, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release and are based on management's assumptions and estimates as of such date. Except as required by law, Kronos Bio assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

    Company contact:

    Stephanie Yao

    Executive Director, Investor Relations and Corporate Communications

    650-525-6605

    Investors:

    Claudia Styslinger

    Argot Partners

    212-600-1902

    Media:

    Sheryl Seapy

    Real Chemistry

    949-903-4750

     



    Primary Logo

    View Full Article Hide Full Article
View All Kronos Bio Inc. News